Literature DB >> 16936272

B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease.

Toshihisa Kawai1, Takashi Matsuyama, Yoshitaka Hosokawa, Seicho Makihira, Makoto Seki, Nadeem Y Karimbux, Reginaldo B Goncalves, Paloma Valverde, Serge Dibart, Yi-Ping Li, Leticia A Miranda, Cory W O Ernst, Yuichi Izumi, Martin A Taubman.   

Abstract

Receptor activator of nuclear factor-kappaB (RANKL)-mediated osteoclastogenesis plays a pivotal role in inflammatory bone resorption. The aim of this study was to identify the cellular source of RANKL in the bone resorptive lesions of periodontal disease. The concentrations of soluble RANKL, but not its decoy receptor osteoprotegerin, measured in diseased tissue homogenates were significantly higher in diseased gingival tissues than in healthy tissues. Double-color confocal microscopic analyses demonstrated less than 20% of both B cells and T cells expressing RANKL in healthy gingival tissues. By contrast, in the abundant mononuclear cells composed of 45% T cells, 50% B cells, and 5% monocytes in diseased gingival tissues, more than 50 and 90% of T cells and B cells, respectively, expressed RANKL. RANKL production by nonlymphoid cells was not distinctly identified. Lymphocytes isolated from gingival tissues of patients induced differentiation of mature osteoclast cells in a RANKL-dependent manner in vitro. However, similarly isolated peripheral blood B and T cells did not induce osteoclast differentiation, unless they were activated in vitro to express RANKL; emphasizing the osteoclastogenic potential of activated RANKL-expressing lymphocytes in periodontal disease tissue. These results suggest that activated T and B cells can be the cellular source of RANKL for bone resorption in periodontal diseased gingival tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936272      PMCID: PMC1698808          DOI: 10.2353/ajpath.2006.060180

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro.

Authors:  Genevieve Gorny; Aubie Shaw; Merry Jo Oursler
Journal:  Exp Cell Res       Date:  2004-03-10       Impact factor: 3.905

2.  Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells.

Authors:  Y Choi; K M Woo; S H Ko; Y J Lee; S J Park; H M Kim; B S Kwon
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

3.  Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection.

Authors:  Y T Teng; H Nguyen; X Gao; Y Y Kong; R M Gorczynski; B Singh; R P Ellen; J M Penninger
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

5.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Authors:  P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

6.  IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro.

Authors:  N J Horwood; J Elliott; T J Martin; M T Gillespie
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

7.  Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity.

Authors:  N Yamada; S Niwa; T Tsujimura; T Iwasaki; A Sugihara; H Futani; S Hayashi; H Okamura; H Akedo; N Terada
Journal:  Bone       Date:  2002-06       Impact factor: 4.398

8.  Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease.

Authors:  Paloma Valverde; Toshihisa Kawai; Martin A Taubman
Journal:  J Bone Miner Res       Date:  2004-01       Impact factor: 6.741

Review 9.  MIP-1 alpha and myeloma bone disease.

Authors:  G David Roodman; Sun Jin Choi
Journal:  Cancer Treat Res       Date:  2004

10.  Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Authors:  H Min; S Morony; I Sarosi; C R Dunstan; C Capparelli; S Scully; G Van; S Kaufman; P J Kostenuik; D L Lacey; W J Boyle; W S Simonet
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  188 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 3.  Cell biology of osteoimmunology.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2010-08-16

Review 4.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

5.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

6.  Antibody to receptor activator of NF-κB ligand ameliorates T cell-mediated periodontal bone resorption.

Authors:  Xiaoping Lin; Xiaozhe Han; Toshihisa Kawai; Martin A Taubman
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

7.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.

Authors:  Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

8.  Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Authors:  Kristine M Erlandson; Maryann OʼRiordan; Danielle Labbato; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

Review 9.  Emerging roles of immunostimulatory oral bacteria in periodontitis development.

Authors:  Yizu Jiao; Mizuho Hasegawa; Naohiro Inohara
Journal:  Trends Microbiol       Date:  2014-01-13       Impact factor: 17.079

10.  RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.

Authors:  Zhenqiang Yao; Wei Lei; Rong Duan; Yanyun Li; Lu Luo; Brendan F Boyce
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.